BioVersys AG (XSWX:BIOV) Construction In Progress: CHF0.00 Mil (As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.00
View Full Analysis

What is BioVersys AG Construction In Progress?

BioVersys AG XSWX:BIOV +1.17% 4 Construction In Progress is CHF0.00 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG Construction In Progress Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Construction In Progress Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Construction In Progress
0.00 0.00

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Construction In Progress 0.00 0.00 0.00 0.00
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of CHF0.00 Mil mean?
BioVersys AG (XSWX:BIOV) has a Construction In Progress of CHF0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Construction In Progress too high?
BioVersys AG's current Construction In Progress is CHF0.00 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Construction In Progress compare to VRTX and REGN?
BioVersys AG's Construction In Progress of CHF0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on BioVersys AG and its competitors. BioVersys AG's current Construction In Progress is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Construction In Progress of CHF0.00 Mil. The current Construction In Progress is CHF0.00 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Construction In Progress is CHF0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.00
Price